Digital data capture technologies provider Kayentis has raised about $8.3m in growth capital in an effort to accelerate the expansion of its digital platform for clinical trials across the globe.
Through the new funding, the company will be able to strengthen its approach in transforming the way pharma, investigator sites and patients engage in clinical trials.
Kayentis CEO Guillaume Juge said: “This new funding is testimony to the trust our shareholders hold in Kayentis’ potential. It shows their confidence in our abilities to fully satisfy the demands for digital data integrity and expertise in the growing clinical trials market.
“Our roadmap is geared towards providing more innovation and operational capacity to support the trend towards virtual, decentralised and remote trials, where patient-facing digital technologies are increasingly playing an important role. These provisions are pivotal in helping our clients bring important therapies to market.”
The new funding will take Kayentis beyond electronic Clinical Outcome Assessment (eCOA) with more options designed to improve the patient experience and support the digitalisation of clinical trials.
Kayentis will use the funding to enrich its ‘Clin’form3 eCOA’ platform with new functionalities and services to support post-Covid ‘new normal’.
Furthermore, the funding will strengthen the company’s roadmap to improve the experience of patients and investigator sites during clinical trials and intensify US developments.
Initially, the company will reinforce the team in Boston and later expand its footprint across North America.
LBO France managing director Franck Noiret said: “We are delighted to lead this round and reinvest in Kayentis through our SISA digital health fund.
“This new capital injection will enable Kayentis to accelerate its technological developments and increase its footprint on the US market.”